Galderma’s investigational monoclonal antibody nemolizumab demonstrated positive results in a late-stage study for treatment of prurigo nodularis, a chronic inflammatory skin disease that includes extreme itchiness.

Prurigo nodularis is associated with an impaired quality of life and frequent sleep deprivation.

After 16 weeks of treatment, the monotherapy demonstrated meaningful improvements, with 38 percent of participants who received the treatment achieving clearance or near-clearance of their skin lesions and 56 percent reporting a significant a reduction in itching.